SRR1397073
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.495
- KRAS_SIGNALING_DN+0.466
- ALLOGRAFT_REJECTION+0.286
- MYOGENESIS+0.253
- KRAS_SIGNALING_UP+0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.213
- ANGIOGENESIS+0.198
- COAGULATION+0.189
- SPERMATOGENESIS+0.183
- INFLAMMATORY_RESPONSE+0.169
Top 10 suppressed
- MYC_TARGETS_V1-0.591
- MYC_TARGETS_V2-0.581
- UNFOLDED_PROTEIN_RESPONSE-0.573
- PROTEIN_SECRETION-0.491
- DNA_REPAIR-0.474
- MTORC1_SIGNALING-0.459
- G2M_CHECKPOINT-0.453
- E2F_TARGETS-0.447
- MITOTIC_SPINDLE-0.396
- OXIDATIVE_PHOSPHORYLATION-0.362
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1440962 | GTEX | — | 0.958 |
| 2 | SRR1451964 | GTEX | — | 0.957 |
| 3 | SRR1474886 | GTEX | — | 0.955 |
| 4 | SRR1416754 | GTEX | — | 0.954 |
| 5 | SRR1316624 | GTEX | — | 0.954 |
| 6 | SRR662091 | GTEX | — | 0.953 |
| 7 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.953 |
| 8 | BS_0X9EGHY2 | low-grade glioma | — | 0.952 |
| 9 | SRR1394713 | GTEX | — | 0.948 |
| 10 | SJEPD001523_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.948 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.495 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.466 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.286 | Idelalisib | — uncovered |
| MYOGENESIS | 0.253 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.213 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.198 | Remibrutinib | — uncovered |
| COAGULATION | 0.189 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.183 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.169 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.168 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.037 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.036 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.026 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.023 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.006 | Inavolisib | — uncovered |